Debevoise & Plimpton LLP is advising JP Morgan Securities Inc. as financial advisor to The Medicines Co. (NASDAQ: MDCO) in its $9.7 billion acquisition by Novartis AG (NASDAQ: NVS), expanding Novartis’ portfolio to include the maker of inclisiran, a drug candidate that lowers cholesterol and showed promise in recent Phase III trials. The two companies will continue to operate independently until the deal has been completed. The transaction is expected to close in the first quarter of 2020. For more information, read The Medicines Company’s press release.

JP Morgan Securities LLC is an investment management company that offers wealth planning, education funding, research, securities, brokerage solutions, consulting programs, and portfolio management services.

The Medicines Company is a biopharmaceutical company with a singular, relentless focus on addressing the greatest global healthcare challenge and burden today – cardiovascular disease.

Novartis AG, a Swiss researcher and manufacturer, is a leading global medicines company that provides solutions to address the evolving needs of patients worldwide.

The Debevoise team was led by M&A partner Andrew Bab and included M&A associates Sean Foley and Priya Soni.